LTF and neoplasm: utilized shikonin (SHK) and JQ1‐co‐delivering mannosylated lactoferrin nanocarrier (Man‐LF NPs) to treat CT26 tumor.[168] Due to the potential of SHK in inhibiting PKM2 to decrease the generation of lactate, and JQ1‐mediated inhibition of PD‐L1 expression, the Man‐LF NPs remarkably increased TAM1/TAM2 ratio, and potentiated tumor‐specific T cell immunity, which led to great reduction of CT26 tumor and prolonged survival time of tumor‐bearing mice.